Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.35 |
| ▸ | GRM6 | O15303 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859959 | 1.00 | HSD11B1 (0.48) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL16698251 | 1.00 | HSD11B1 (0.48) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL28134791 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL27917064 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL15772802 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL28134798 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| Hydrochloric Acid SCHEMBL3051989 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL28134787 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL31349739 | 0.97 | HSD11B1 (0.46) | HSD11B1CYP2C9POLBTDP1HSD17B10 | |
| SCHEMBL29099215 | 0.84 | POLB (0.43) | POLBTDP1TSHRAPEX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143185-B1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-10-29 | — | — | EP | claimed |
| CN-118909607-B | Degradable oil-soluble temporary plugging agent and preparation method thereof | 西安石油大油气科技有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119143638-A | Preparation method of 2-adamantanoic acid-trifluoropropane sulfonic acid-derived high-purity electronic grade photoinduced acid generator | 苏州威迈芯材半导体有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-118909607-A | Degradable oil-soluble temporary plugging agent and preparation method thereof | 西安石油大油气科技有限公司 | 2024-11-08 | — | — | CN | claimed |
| US-20200253954-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-08-13 | — | — | US | claimed |
| CN-107400058-B | The synthetic method of 2,4,6- trimethylbenzene -1,3,5- triamine and N, N, N- trisacylated products | 北京理工大学 | 2019-08-09 | — | — | CN | claimed |
| CN-107400058-A | The synthetic method of 2,4,6- trimethylbenzene -1,3,5- triamines and N, N, N- trisacylated products | 北京理工大学 | 2017-11-28 | — | — | CN | claimed |
| CN-105294428-B | 2-adamantanecarboxylic acid and 1-adamantane methanol separation and purification method | 浙江师范大学 | 2017-05-10 | — | — | CN | claimed |
| CN-105294428-A | 2-adamantanecarboxylic acid and 1-adamantane methanol separation and purification method | UNIV ZHEJIANG NORMAL | 2016-02-03 | — | — | CN | claimed |
| CN-102249900-B | Method for separation and purification of 2-adamantanecarboxylic acid and 1-adamantanecarboxylic acid | UNIV ZHEJIANG NORMAL | 2013-09-18 | — | — | CN | claimed |
| US-20120318969-A1 | METHOD FOR THE DIFFERENTIATION OF ALTERNATIVE SOURCES OF NAPHTHENIC ACIDS | UNIVERSITY OF PLYMOUTH (GB) | 2012-12-20 | — | — | US | claimed |
| CN-102249900-A | Method for separation and purification of 2-adamantanecarboxylic acid and 1-adamantanecarboxylic acid | UNIV ZHEJIANG NORMAL | 2011-11-23 | — | — | CN | claimed |
| US-5965579-A | ANTAGONISTS OF THE NEUROTENSIN RECEPTORS; INCREASING AFFINITY FOR HUMAN NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-10-12 | — | — | US | claimed |
| US-5939449-A | NOVEL COMPOUNDS HAVING HIGH AFFINITY FOR THE NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-08-17 | — | — | US | claimed |
| CN-1184469-A | 1-phenyl-3-pyrazolecarboxamides active on neurotensin receptors | SANOFI SA (FR) | 1998-06-10 | — | — | CN | claimed |
| US-5723483-A | NEUROTENSIN ANTAGONIST, HYPOTENSIVE AGENTS AND FOR NEUROPSYCHIATRIC DISORDERS | SANOFI (FR) | 1998-03-03 | — | — | US | claimed |
| EP-0119359-B1 | ADAMANTYL CARBOXYLIC AND SULFONIC ACID CATALYZED PARAFFIN-OLEFIN ALKYLATION AND PARAFFIN ISOMERIZATION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1987-06-10 | — | — | EP | claimed |
| EP-0119359-A1 | Adamantyl carboxylic and sulfonic acid catalyzed paraffin-olefin alkylation and paraffin isomerization | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1984-09-26 | — | — | EP | claimed |
| US-4426545-A | Adamantyl carboxylic and sulfonic acid catalyzed paraffin-olefin alkylation | EXXON RESEARCH AND ENGINEERING CO. (US) | 1984-01-17 | — | — | US | claimed |
| US-4424387-A | STRONG ACID, BRANCHING | EXXON RESEARCH AND ENGINEERING CO. (US) | 1984-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253954-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HSD11B1 4136/4885CYP2C9 4859/4885POLB 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.